Navigation Links
Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013

LAWRENCEVILLE, N.J., Aug. 1, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it would hold a conference call to discuss second quarter 2013 results at 11:00 a.m. EDT on Thursday, August 8, 2013. To participate in the call, interested parties may dial 1-800-723-6498 (Toll-Free/North America) or 1-785-830-7989 (International/Toll) and ask for The Celsion Corporation Second Quarter 2013 Financial Results Conference Call (Conference Code: 3083628) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at

The call will be archived for replay on Thursday, August 8, 2013 at 2:00 p.m. EDT and will remain available until Thursday, August 22, 2013. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 3083628. An audio replay of the call will also be available on the Company's website,, for 30 days after 2:00 p.m. EDT on Thursday, August 8, 2013.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website:

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church
Sr. Vice President and Chief Financial Officer

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
2. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
3. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
4. Comprehensive Care Corporation Signs Agreement With A National Leader In Pharmacy Benefit Management
5. Luminex Corporation Reports Second Quarter 2013 Results
6. CVS Caremark Corporation To Hold Second Quarter 2013 Conference Call
7. MGC Diagnostics Corporation to Present at the Southern California Investor Conference on Thursday, August 8, 2013
8. FMC Corporation overtar ledende høy-rene Omega-3 konsentratprodusent Epax AS
9. FMC Corporation Acquires Leading High-Purity Omega-3 Concentrates Producer Epax AS
10. Luminex Corporation Achieves Milestone, Ships 10,000th Instrument
11. CVS Caremark Corporation Announces Quarterly Dividend
Post Your Comments:
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):